Kaiser Permanente - Oakland ( Site 0047)(9.6 mi away)Contact
+79 other location
classical hodgkin lymphoma
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination
with chemotherapy in children and young adults with newly diagnosed classical Hodgkin
Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
Group 1 will consist of low-risk participants with cHL Stages IA, IB and IIA without bulky
disease. Group 2 will consist of high-risk participants with cHL Stages IIEB, IIIEA, IIIEB,
IIIB, IVA and IVB.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.